Your browser doesn't support javascript.
First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.
Tanaka, Sébastien; Begue, Floran; Veeren, Bryan; Tran-Dinh, Alexy; Robert, Tiphaine; Tashk, Parvine; Lortat-Jacob, Brice; Faille, Dorothée; de Chaisemartin, Luc; Zappella, Nathalie; Atchade, Enora; Kramer, Laura; Montravers, Philippe; Meilhac, Olivier.
  • Tanaka S; AP-HP, Service d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • Begue F; INSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, France.
  • Veeren B; INSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, France.
  • Tran-Dinh A; INSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, France.
  • Robert T; AP-HP, Service d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • Tashk P; Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, 75006 Paris, France.
  • Lortat-Jacob B; INSERM U1148, Laboratory for Vascular Translational Science, 75018 Paris, France.
  • Faille D; AP-HP, Service de Biochimie, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • de Chaisemartin L; AP-HP, Service d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • Zappella N; AP-HP, Service d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • Atchade E; Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, 75006 Paris, France.
  • Kramer L; INSERM U1148, Laboratory for Vascular Translational Science, 75018 Paris, France.
  • Montravers P; AP-HP, Département d'Hématologie Biologique, CHU Bichat-Claude Bernard, 75018 Paris, France.
  • Meilhac O; AP-HP, Département d'Immunologie, CHU Bichat-Claude Bernard, 75018 Paris, France.
Biomedicines ; 10(4)2022 Mar 23.
Article in English | MEDLINE | ID: covidwho-1834700
ABSTRACT
High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10040754

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10040754